TNFR-associated factor 1 (TRAF1) and TRAF2 have been demonstrated to inhibit apoptosis and promote cell survival in glioblastoma (GBM) cells with experiments in vitro. However, their clinical and prognostic significance have not been elucidated.
Background
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults; it has strong therapy resistance, high recurrence, and rapid progression [1] . GBM represents 15% to 20% of all primary intracranial tumors [2] . The treatment of GBM has improved significantly in recent years, including new surgical methods, equipment, and multi-drug therapies such as temozolomide [3] . However, the survival rate and survival time of patients with GBM is still very low, with a median survival time about 14.6 months [4] . Standardized treatments of GBM include surgical resection and combined radio-chemotherapy, which have little effect on some aggressive subtypes of GBM [5] .
Tumor necrosis factors (TNF) play a pivotal role in cellular apoptosis controlled by binding with their receptors, TNFRs. In GBM, these TNFRs include TNFR1, TRAILDR4, TRAIL-DR5, and Fas, etc. [6, 7] . TNFs play an anti-apoptotic role via interacting with some other receptors. Therefore, the effects of TNFs are not certain, mainly depending on the downstream receptors, which determine the balance between pro-apoptotic and anti-apoptotic pathways. In the numerous signaling pathways triggered by TNFs, the TNFR-associated factor (TRAF) family can mediate the TNF-induced NF-kB activation in GBM cells and also in other tumor cells, resulting in both cytokine secretion and resistance to apoptosis [8] . The TRAF family consists of 6 adapter proteins (TRAF1-TRAF6). In the TRAF family, recent evidence suggested the anti-apoptotic activity of TRAF1 and TRAF2 in GBM cells [9] . However, the prognostic value of TRAF1 and TRAF2 is still not known.
In our study, we investigated the expression of TRAF1 and TRAF2 in GBM tissues for the first time. Moreover, we evaluated the influence of TRAF1/2 on clinicopathologic factors. We further performed univariate analysis and multivariate analysis to estimate the prognostic value of TRAF1 and TRAF2 in patients with GBM.
Material and Methods

Patients and follow-ups
A total of 105 patients were diagnosed as having GBM and underwent surgical resection in our study, which were enrolled into our cohort according to the criteria: (1) available followup and samples; (2) post-operational survival time more than 2 months; and (3) no adjuvant therapy after operation. All the patients in the cohort underwent macroscopic total or neartotal tumor resection and we performed evaluation using the Karnofsky Performance Scale (KPS). The overall survival time was calculated from the operation to the date of death or censored at the date of the last follow-up examination. The average survival time was 7.99 months and the median survival time was 7 months. All the samples were obtained with prior content of patients and the approval of Ethics Committee. The study was approved by the Ethics Committee of Yidu Central Hospital and Linyi People's Hospital.
Immunohistochemistry
The expression of TRAF1 and TRAF2 was detected with immunohistochemistry (IHC) in a streptavidin-biotin immunoperoxidase method [10, 11] . All the slides were first soaked in xylene and degraded ethanol for dewaxing. After that, slides were incubated in 3% hydrogen peroxide to achieve endogenous peroxidase inactivation. Moreover, citrate buffer was used for antigen retrieval and 5% bovine serum albumin was applied for blocking unspecific binding. Primary antibodies of TRAF1 (1: 200, Cell Signaling Technology, Danvers, MA, USA), TRAF2 (1: 100, Abcam, Cambridge, UK), or Ki67(1: 100, DAKO, Denmark) were used to incubate the samples in 4°C overnight, followed by washing in phosphate-buffered saline. Corresponding secondary antibodies and streptavidin peroxidase complex reagent were then applied. Finally, the results were visualized in 3,3'-diaminobenzidine solution.
Score system of IHC results
Slides were blindly scored by 2 independent pathologists unaware of the clinical data. The results of IHC included 2 aspects: the staining intensity and the proportion of positively-stained tumor cells, referring to previous studies [12, 13] . The final score of IHC is the product of the score (staining intensity) multiplied by the score (positively-stained tumor cells). The score of positively-stained tumor cells was defined as: score 0 for <5% positive tumor cells; score 1 for 6-30% positive tumor cells; score 2 for 31-50% positive tumor cells; and score 3 for more than 50% positive tumor cells. The staining intensity was defined as: 0 for no staining, 1 for weak staining, 2 for moderate staining, and 3 for strong staining. The cut-off was identified by the ROC curve of IHC score according to a previous study [14] , dividing the cohort into TRAF1/2 high-expression or low-expression.
Statistical analysis
All the data in our study were analyzed with SPSS17.0 software (IBM Corporation, Armonk, New York, U.S). The correlation between TRAF1/2 and clinicopathologic features was evaluated by chi-square test. Relevant factors with overall survival rate were investigated by Kaplan-Meier method, and the difference in survival curves was analyzed by log-rank test. The independent prognostic factors were identified with the Cox regression proportional hazards model. P<0.05 was considered statistically significant.
Results
Expression of TRAF1 and TRAF2 in GBM tissue
A total of 105 patients with GBM were enrolled in our study, and their basic information is displayed in Table 1 . There were 58 female patients and 47 male patients in our cohort. In formalin-fixed tissues, the expression of TRAF1 and TRAF2 was detected to show their location and abundance. TRAF1 and TRAF2 were mainly expressed in cytoplasm ( Figure 1A , 1B). TRAF2 was occasionally observed in the cell nucleus but TRAF1 was not. The cohort was further divided into high-expression and low-expression groups according to the expression of TRAF1 and TRAF2. The percentage of TRAF1 and TRAF2 high expression was 30.48% (32/105) and 40.95% (43/105), respectively.
Association of TRAF1/2 with clinicopathologic factors
The correlation between TRAF1, TRAF2, and clinicopathologic factors, including age, gender, KPS, resection margin, and Ki67 percentage, was analyzed with chi-square test (Table 2) . Unfortunately, there was no significant relevant factor of TRAF1 or TRAF2 in our test, indicating that TRAF1/2 expression is not influenced by patient age, gender, or other factors.
Prognostic significance of TRAF1/2
In in vitro experiments, both TRAF1 and TRAF2 have been indicated to promote the progression of GBM cells in previous studies [9, 15] Table 1 . Characteristics of patients.
KPS -Karnofsky Performance Scale; TRAF1 -TNF receptorassociated factor 1; TRAF2 -TNF receptor-associated factor 2. value of TRAF1 and TRAF2. Univariate analysis was first carried out with Kaplan-Meier analysis to examine the factors significantly associated with overall survival rate ( Table 3) . In our study, the extent of resection (P<0.001) and Ki67 (P=0.001) ( Figure 2A ) were both significantly associated with overall survival rate. Moreover, TRAF2 high expression was proved to predict poorer prognosis, while TRAF1 expression had no similar influence on survival rate ( Figure 2B, 2C) . Additionally, the KPS score system appeared to influence prognosis of patients with GBM, but the tendency was not statistical significant (P=0.086). Lower KPS score reflects worse overall condition of patients who need more careful nursing and attention. Patients with lower KPS usually had worse survival rates than those with higher KPS.
To further identify the independent prognostic factors of GBM, multivariate analysis was performed with the Cox regression model. All the clinicopathologic factors were enrolled. The resection extent (P<0.001) was identified as a prognostic risk in our cohort, and it was obvious that positive extent indicated unfavorable prognosis. High percentage of Ki67(P=0.002) alone also predicted worse prognosis of GBM in our study. Additionally, TRAF2 expression was confirmed to be an independent prognostic factor in GBM, meaning TRAF2 high-expression itself can predict worse prognosis of patients with GBM (P=0.046, HR=2.13). containing death domains, such as Fas-associated death domain or TNFR-associated death domain, can induce apoptosis. Emerging evidence supports the oncologic role of aberrant expression of TRAF1 or TRAF2. For example, TRAF1 activation can promote lymphoid malignancies by its apoptosis-inhibition effect [17] . In GBM cells, activation of NF-kB p65 and its downstream TRAF1 was demonstrated to inhibit cell apoptosis and facilitate cell survival [18] . Angileri et al. demonstrated that NF-kB and its downstream proteins, such as TRAF1 and survivin, are up-regulated in gliomas. For TRAF2, the mRNA level between low-grade astrocytoma and GBM had no significant difference [8] . However, the detection of mRNA level is much different from the protein level detected by IHC, and we focused on comparing the prognostic value of TRAF1 and TRAF2 instead of comparing their mRNA level between normal tissues and glioma tissues.
Discussion
TRAF2 is considered to play an essential role in TNF signaling, but this hypothesis has not been verified in all tissues. Previous studies suggested that TRAF2 protects cells from TNF-induced death [19] . There are conflicting data on the role of TRAF2 in TNF signaling, and the role of TRAF2 in tumors is also controversial. Schneider recently reported that TRAF2 inhibits the carcinogenesis of hepatocellular carcinoma [20] , while Etemadi et al. demonstrated that TRAF2 regulates TNF and NF-kB signaling to suppress apoptosis in in vivo and in vitro experiments [21] . In GBM, TRAF2 silencing blocks the activation of NF-kB signaling and suppresses cell growth, indicating TRAF2 as an attractive drug target for anticancer therapy of GBM [22] .
In our cohort, we did not find a significant correlation between age and KPS score with overall survival rate, which has been demonstrated in some previous studies [23] [24] [25] , possibly because our cohort size was small, but this did not affect the variability of the cohort and our demonstration of TRAF2 as a prognostic factor. Table 3 . Prognostic value of TRAF1 and TRAF2.
* Means calculated by log-rank test; $ means calculated by Cox-regression model. KPS -Karnofsky Performance Scale; TRAF1 -TNF receptor-associated factor 1; TRAF2 -TNF receptor-associated factor 2.
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Additionally, numerous signaling modulators participate in regulation of downstream signal transduction pathways. Their cross-talk provides more complicated signaling abundance and variety [16] . Even in the TNF signaling pathway, TRAF2 exerts multiple receptor-specific functions and mediates cross-talk between TNFR1 and TNFR2. TRAF2 could be a positive or negative regulator of TNF-mediated signaling [26] . In GBM, the exploration of TRAF1/2 and their influence on signaling pathway and oncological effects are not clear. We demonstrated that overexpression of TRAF2 rather than TRAF1 could lead to unfavorable prognosis of GBM. This could provide new insight into the search for effective biomarkers of GBM, and may help stratify high-risk patients more clearly. Unfortunately, we have not explored the mechanisms by which TRAF2 overexpression results in worse prognosis, because of the complicated TNF signaling network described above. However, the study of molecular mechanisms is essential and helpful for finding novel drug targets in TRAF2 downstream signaling. We hope our results trigger interest in TRAF2 in GBM and accelerate associated studies to find more effective therapies.
Conclusions
We, for the first time, investigated the expression of TRAF1 and TRAF2 in GBM tissues and evaluated their clinical significance, including their association with clinicopathologic factors and prognostic value. We demonstrated that high expression of TRAF2, but not TRAF1, can predict worse prognosis of GBM, and it was identified as an independent biomarker in GBM prognosis.
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